Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Influenza vaccine

Executive Summary

Trivalent 1998-1999 flu vaccine formulation should include A/Sydney/05/97-like strain rather than A/Wuhan/359/95-like strain as the H3N2 component, FDA's Vaccines & Related Biological Products Advisory Committee recommends March 23. An estimated 77.7% of Type A H3N2 influenza in the U.S. this season has been Sydney-like. The H1N1 component will be A/Beijing/262/95-like, a change from the A/Bayern/07/95-like strain. The committee voted in January to keep the influenza B component as B/Harbin/07/94 ("The Pink Sheet" Feb. 2, In Brief)
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel